This biotechnology company develops therapeutics targeting mitochondrial dysfunction to treat cardiometabolic diseases. Their lead program focuses on reversing diabetic cardiovascular disease, aiming to improve health outcomes for individuals with diabetes.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiometabolic diseases, such as diabetic cardiovascular disease, pose a significant threat to individuals with diabetes. Current treatment options often fail to address the underlying mitochondrial dysfunction contributing to these conditions.
Solution
Sanacor is developing therapeutics that target and correct mitochondrial dysfunction to treat cardiometabolic diseases. Their lead program focuses on reversing diabetic cardiovascular disease by addressing the dysregulation of Fis1, a mitochondrial protein involved in mitochondrial fission. By modulating Fis1 activity, Sanacor aims to restore healthy mitochondrial function, thereby improving cardiovascular health outcomes for individuals with diabetes. This approach seeks to provide a more targeted and effective treatment option compared to existing therapies.
Target Audience
The primary target audience includes individuals with diabetes who are at risk of or are currently suffering from cardiovascular complications, as well as healthcare providers specializing in cardiometabolic diseases.
Features
- Therapeutics targeting Fis1, a key regulator of mitochondrial fission
- Focus on reversing diabetic cardiovascular disease by restoring mitochondrial function
- Modulation of mitochondrial dynamics to improve cellular energy production